Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Fosun Pharma Partners with Clavis Bio in $362.5M Strategic Collaboration

Fineline Cube Dec 21, 2025
Company Deals

Leadingtac Raises RMB 200M Series B to Advance Protein Degradation Pipeline

Fineline Cube Dec 20, 2025
Company Deals

Baiyunshan to Acquire Zhejiang Pharma‑Industry for $500.5M, Expanding Distribution Network

Fineline Cube Dec 19, 2025
Company Deals

InSilico Medicine Debuts on HKEX in $2.3B IPO, Valuing AI Drug Platform at $1.5B

Fineline Cube Dec 18, 2025
Company Deals

Sirnaomics Partners on $42M Small Nucleic Acid Fund in Hangzhou

Fineline Cube Dec 18, 2025
Policy / Regulatory

China Mandates Specialty Departments in Primary Care by 2030

Fineline Cube Dec 18, 2025
Company Drug

EPI-003 Wins FDA IND as First LNP Epigenetic Therapy for Hepatitis B

Fineline Cube Dec 21, 2025
Company Drug

SanegeneBio’s INHBE siRNA Wins China IND for Obesity as First RNAi Target

Fineline Cube Dec 21, 2025
Company Drug

Staidson and J&J’s Teclistamab Gain Breakthrough Designation for Hemophilia and Myeloma

Fineline Cube Aug 30, 2022

The Center for Drug Evaluation (CDE) has indicated that Staidson (Beijing) Pharmaceutical Co., Ltd’s (SHE:...

Company Deals

Fosun Pharma to Invest RMB 1B in Chengdu Vaccine Base

Fineline Cube Aug 30, 2022

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) announced that its subsidiaries, Shanghai Fosun Pharmaceutical...

Company Drug

InnoCare Pharma and CStone Pharmaceuticals’ Drugs Receive Prioritized CDE Review

Fineline Cube Aug 30, 2022

The Center for Drug Evaluation (CDE) has granted prioritized review status to InnoCare Pharma’s (HKG:...

Company Deals Digital

Luca Healthcare Raises Pre-Series A Funding for Digital Biomarker R&D

Fineline Cube Aug 30, 2022

Shanghai-based Luca Healthcare Co., Ltd, a firm specializing in digital biomarkers and therapeutics, has raised...

Company Drug

Biocytogen and Tracon Pharmaceuticals Gain FDA IND Approval for Sarcoma Trial

Fineline Cube Aug 30, 2022

China-based Biocytogen (Beijing) Co., Ltd and US-based Tracon Pharmaceuticals Inc. (Nasdaq: TCON) announced that the...

Company Drug

Hengrui Medicine’s Dalpiciclib Hits Superiority Criteria in Phase III Study

Fineline Cube Aug 30, 2022

China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) announced that its Phase III SHR6390-III-302 study...

Company

Ascentage Pharma’s H1 2022 Revenue Surges 636.9% on Olverembatinib Sales

Fineline Cube Aug 29, 2022

China-based Ascentage Pharma (HKG: 6855) reported a significant increase in revenue for the six months...

Company Policy / Regulatory

China-U.S. Listing Agreement Clears Path for Chinese Firms to Stay Listed in the U.S.

Fineline Cube Aug 29, 2022

China and the United States are nearing an agreement that would allow Chinese firms to...

Policy / Regulatory

Shandong Releases Off-Label Drug Use Consensus, Expanding Clinical Guidance

Fineline Cube Aug 29, 2022

The Shandong Pharmaceutical Association (SPA) has released the “Shandong Province Expert Consensus on Off-label Drug...

Company Drug

ImmuneOnco’s IMM40H Receives NMPA Clinical Trial Approval for CD70 Antibody

Fineline Cube Aug 29, 2022

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd announced that it has received clinical trial approval from the...

Company Deals

InnoCare Pharma Files for STAR Market IPO to Raise RMB 4B for Drug R&D

Fineline Cube Aug 29, 2022

China-based InnoCare Pharma (HKG: 9969) has filed for an initial public offering (IPO) on the...

Policy / Regulatory

NMPA Releases 57th Batch of Reference Drugs for Generic Consistency Evaluation

Fineline Cube Aug 29, 2022

The National Medical Products Administration (NMPA) has released the 57th batch of reference drugs for...

Company Deals Hospital

J&J MedTech Joins China’s Surgical Training Program to Skill Up Surgeons

Fineline Cube Aug 29, 2022

The National Institute of Hospital Administration (NIHA) and the National Health Commission (NHC) launched the...

Company Drug

Sirnaomics’ STP705 Achieves 100% Complete Remission in Basal Cell Carcinoma Study

Fineline Cube Aug 29, 2022

Sino-US siRNA therapy developer Sirnaomics Ltd (HKG: 2257) announced positive results from a Phase II...

Policy / Regulatory

NMPA Reclassifies Omeprazole Tablets from Prescription to OTC Status

Fineline Cube Aug 29, 2022

The National Medical Products Administration (NMPA) announced that omeprazole enteric-coated tablets have been reclassified from...

Company Drug

Henlius Biotech’s PD-1 Inhibitor Serplulimab Secures NMPA Review for Esophageal Cancer

Fineline Cube Aug 29, 2022

Shanghai Henlius Biotech Inc. (HKG: 2696) announced that the National Medical Products Administration (NMPA) has...

Company Deals

Acchrom Tech Raises USD 14.45M in Angel Round Led by BioTrack Capital to Expand Chromatography Solutions

Fineline Cube Aug 29, 2022

Beijing-based chromatography specialist Acchrom Tech has raised RMB 100 million (USD 14.45 million) in an...

Company Legal / IP

JD Healthcare’s H1 2022 Financial Report Shows Strong Growth in Revenue and Profits

Fineline Cube Aug 26, 2022

JD Healthcare, a unit of China’s e-commerce giant JD.com (NASDAQ: JD), reported robust financial results...

Company

Everest Medicines CEO Resigns as Trodelvy Sale Completed

Fineline Cube Aug 26, 2022

China-based biotech Everest Medicines (HKG: 1952) announced the resignation of CEO Dr. Kerry Blanchard, effective...

Company Deals

Shanghai Bao Pharma Raises USD 100M in Series B to Advance Drug Delivery Tech

Fineline Cube Aug 26, 2022

Shanghai Bao Pharmaceuticals Co., Ltd has raised over USD 100 million in a Series B...

Posts pagination

1 … 565 566 567 … 600

Recent updates

  • EPI-003 Wins FDA IND as First LNP Epigenetic Therapy for Hepatitis B
  • SanegeneBio’s INHBE siRNA Wins China IND for Obesity as First RNAi Target
  • Fosun Pharma Partners with Clavis Bio in $362.5M Strategic Collaboration
  • BeOne Medicines Wins FDA Fast Track for GPC3 Bispecific in Liver Cancer
  • BeOne Medicines Names Dual Presidents in Leadership Overhaul
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

EPI-003 Wins FDA IND as First LNP Epigenetic Therapy for Hepatitis B

Company Drug

SanegeneBio’s INHBE siRNA Wins China IND for Obesity as First RNAi Target

Company Deals

Fosun Pharma Partners with Clavis Bio in $362.5M Strategic Collaboration

Company Drug

BeOne Medicines Wins FDA Fast Track for GPC3 Bispecific in Liver Cancer

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.